Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
The European Commission has approved Exdensur, the first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This approval marks a significant advancement in treatment options for patients suffering from these respiratory diseases.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.